Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shattuck Labs ( (STTK) ) has shared an announcement.
On January 22, 2026, Shattuck Labs, Inc. entered into a sales agreement with Leerink Partners LLC to offer and sell from time to time up to $75 million of its common stock through an at-the-market equity program registered under an effective shelf registration statement. The company is not obligated to sell any shares and may suspend or terminate the program at any time, while Leerink Partners will act as sales agent on mutually agreed terms in exchange for a commission of up to 3% of gross proceeds plus expense reimbursement. Shattuck Labs plans to use any proceeds from this flexible financing vehicle to fund ongoing and planned clinical trials, develop additional product candidates, and support working capital and general corporate needs, potentially strengthening its balance sheet and providing incremental funding capacity for its R&D pipeline.
The most recent analyst rating on (STTK) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Shattuck Labs stock, see the STTK Stock Forecast page.
Spark’s Take on STTK Stock
According to Spark, TipRanks’ AI Analyst, STTK is a Neutral.
The score is held back primarily by weak financial performance: steep revenue decline, large ongoing losses, and significant cash burn. A strong technical uptrend supports the score, but extremely overbought indicators increase near-term downside risk. Valuation is also a headwind because losses make the P/E less meaningful and there is no dividend yield data.
To see Spark’s full report on STTK stock, click here.
More about Shattuck Labs
Shattuck Labs, Inc. is a biotechnology company focused on developing clinical-stage product candidates, with an emphasis on advancing ongoing and planned clinical trials and expanding its pipeline of additional therapeutic candidates. The company allocates capital toward research and development activities, working capital, and general corporate purposes to support its growth in the biopharmaceutical sector.
Average Trading Volume: 378,721
Technical Sentiment Signal: Buy
Current Market Cap: $274.6M
For detailed information about STTK stock, go to TipRanks’ Stock Analysis page.